Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. AustraliŽ
  4. Australian Stock Exchange
  5. Ansell Limited
  6. Nieuws
  7. Overzicht
    ANN   AU000000ANN9

ANSELL LIMITED

(ANN)
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener

Ansell Limited : On the front line

28/05/2020 | 14:08

Formerly a subsidiary of Dunlop, Ansell is an Australian manufacturer of protective gear ó such as gloves, masks, aprons and coveralls ó for industrial and medical applications.

The company was well-known as a condom manufacturer — it owned the premium brand Skyn — but chose to divest this business in 2017, as industry-wide overcapacity and slowing growth across emerging markets depressed earnings with no recovery in sight.

zb_graphique_de_cours



To management's credit, the USD $520mil sale of the condom business to a Chinese consortium came at the upper end of analysts' expectations. It enabled Ansell to pursue its transformation towards the personal protection business for healthcare, life sciences and industrial workers.

The latter required a series of acquisitions to build up a comprehensive portfolio, with $1.1bn spent on external growth over the 2010-2019 period. Divestments funded half of that amount, fresh equity — $359mil at about $30 per share six years ago — and debt issues the other half.

Total return on investment remains modest, but that isn't management's fault. In effect, the protective gear industry is saturated and commoditized, with no barriers to entry as well as market share gains primarily driven by pricing. There characteristics put a ceiling on organic growth prospects and achievable margins.

Still, the portfolio revamp coupled with an extensive restructuring of manufacturing operations improved operating margins by ~150-200bps, "unusual" costs included. Ansell optimized its footprint and closed three plants — in Mexico and South Korea — while upgrading existing facilities in Vietnam, Malaysia, Sri Lanka and Bangkok.

As in every commodity business, survival rests upon counting among the lowest cost operators. The manufacturing base is undemanding in terms of investments — with capital expenditures of ~$50-60mil against cash from operations of ~$180-220mil — but pricey acquisitions are necessary to achieve growth. Going forward, management made no mystery of their intention to complete at least one buyout per year.

Solid financial standing should support these efforts. Total liabilities of $966mil are almost fully covered by current assets, of which $397mil in cash. Balance sheet strength provides substantial investment flexibility, with $1.2bn in M&A capacity and interest expense ($19mil) covered x12 by operating earnings before depreciation and amortization ($237mil).

Following its streak of acquisitions, the company has redirected cash-flows towards returns of capital to shareholders. Distribution of dividends increased from $50mil in 2013 to $62mil in 2019. Share buybacks reached $364mil over the last four years, as the stock traded at about x16-x18 EPS. The fact that management favored buybacks over distributions suggests that they expect earnings growth above industry averages over the next decade. Analysts think likewise.

Speaking of management, the team that took over in 2005 and restructured the company — which had been weakened by many years of underinvestment at Dunlop — is retiring. Chairman Glenn Barnes has already departed, and CEO Magnus Nicolin should pass the baton before next year.  The duo leaves a solid foundation to the new leadership, who steps in as a dramatic economic downturn is unfolding.

Nevertheless, Ansell's business should prove relatively immune to the crisis, at least within the healthcare segment — roughly half of consolidated revenue — for the company obviously stands on the front lines of combating the spread of COVID-19. It is currently booking record orders for gloves, masks and other protective gears, and that trend shouldn't abate any time soon.

These events also came as it was delivering solid results, propped up by a balanced portfolio, solid momentum in the industrial business, as well as a strong U.S. dollar — although Australian, the company invoices its clients and reports its results in the American currency.

These developments have led analysts — whose consensus is surveyed in real time by MarketScreener — to raise their ratings and estimates, even with the stock trading at x19 forward earnings . The latter has been added to the Europa One fund that Surperformance — MarketScreener's editor and parent company — advises on an exclusive basis.


© MarketScreener.com 2020
Cijfers genoemd in het artikel
Verschil (%)KoersVerschil t.o.v. 1 jan (%)
AMP LIMITED -2.55%0.955 uitgestelde koers.-5.45%
ANSELL LIMITED -0.44%34.1 uitgestelde koers.8.22%
EURO / US DOLLAR (EUR/USD) -0.36%1.1414 uitgestelde koers.0.75%
EUROPA ONE I -0.27%133.32 slotkoers.-0.55%
EUROPA ONE R -0.26%173.55 slotkoers.-0.57%
TEAM, INC. -5.41%0.825 uitgestelde koers.-24.31%
THE NEW HOME COMPANY INC. 0.00%8.99 slotkoers.91.68%
Nieuws over ANSELL LIMITED
2021ANSELL LIMITED : Onthechting van dividendslotdividend
FA
2021Nettowinst Ansell stijgt in boekjaar 21 dankzij hogere verkoop van producten voor perso..
MT
2021Ansell Limited kondigt gewoon dividend aan voor de periode van zes maanden afgesloten o..
CI
2021Ansell Limited geeft winstverwachting voor het boekjaar 2022
CI
2021Ansell benoemt algemeen directeur en CEO
MT
2021Ansell Limited geeft winstverwachting voor de tweede helft van 2021
CI
2021Ansell Limited herziet de winstverwachting voor het boekjaar 2021
CI
2021ANSELL LIMITED : Onthechting van dividendinterim-dividend
FA
2021Nettowinst en omzet Ansell stijgen in juli-december 2020; dividend wordt met meer dan 5..
MT
2021Ansell Limited herziet financiële vooruitzichten voor boekjaar 2021
CI
Meer nieuws
Analistenadviezen over ANSELL LIMITED
Meer adviezen
FinanciŽle cijfers
Omzet 2022 1 988 M - 1 742 M
Nettowinst (verlies) 2022 223 M - 195 M
Nettoschuld 2022 133 M - 116 M
Koers/winst-verhouding 2022 14,3x
Dividendrendement 2022 3,08%
Marktkapitalisatie 3 137 M 3 146 M 2 749 M
Beurskap. / Omzet 2022 1,65x
Beurskap. / Omzet 2023 1,62x
Aantal werknemrs 14 159
Percentage vrij verhandelbaar -
Volgende evenement op ANSELL LIMITED
Evolutie van de resultatenrekening
Consensus
Verkoop
Koop
Gemiddeld advies Accumuleren
Aantal analisten 12
Laatste slotkoers 24,57 $
Gemiddelde koersdoel 28,76 $
Spread / Gemiddelde doel 17,1%
Herzieningen van WPA
Managers en directeuren
Neil I. Salmon Chief Executive Officer & Managing Director
Zubair Javeed Chief Financial Officer
John Andrew Bevan Chairman
Giri Peddinti Global Chief Information Officer & Senior VP
John Marsden Senior Vice President-Global Operations
Sector en concurrentie
Verschil t.o.v. 1 jan (%)Kapitalisatie (M$)
ANSELL LIMITED8.22%3 146
ABBOTT LABORATORIES-8.94%219 790
MEDTRONIC PLC4.93%145 952
BECTON, DICKINSON AND COMPANY4.43%74 858
HOYA CORPORATION-10.96%49 369
DEXCOM, INC.-16.69%43 357